TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Pharmaceutical Preparations · NYSE · SEC CIK 818686 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-16.4%
TTM net income YoY-28.9%
TTM EPS YoY-29.5%
Revenue 3-yr CAGR-2.8%
Net income 3-yr CAGR—
Margins
Gross margin65.8%
Operating margin10.2%
Net margin3.6%
FCF margin8.8%
EBITDA margin17.3%
Returns
ROE6.6%
ROA1.3%
ROIC (approx.)32.1%
Asset turnover0.35x
Leverage & solvency
Liabilities / assets80.1%
Debt / equity0.00x
Current ratio0.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.50x
Accruals ratio-3.2%
Payout ratio—
Capex / revenue3.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.39B | $4.14B | $3.98B | $1.50B | $4.48B | $4.18B | $3.89B | $4.23B |
| Cost of revenue | $1.96B | $1.99B | $2.01B | $2.06B | $2.18B | $2.07B | $2.01B | $2.11B |
| Gross profit | $2.44B | $2.15B | $1.97B | $2.66B | $2.30B | $2.10B | $1.88B | $2.12B |
| R&D expense | $297.00M | $970.00M | $222.00M | $267.00M | $256.00M | $244.00M | $247.00M | $247.00M |
| SG&A expense | $298.00M | $317.00M | $304.00M | $367.00M | $317.00M | $305.00M | $297.00M | $302.00M |
| Operating income | $714.00M | -$231.00M | $652.00M | $300.00M | $882.00M | $455.00M | $519.00M | -$29.00M |
| Pretax income | $300.00M | -$455.00M | $437.00M | $80.00M | $646.00M | $203.00M | $294.00M | -$247.00M |
| Income tax | $66.00M | $121.00M | $67.00M | -$390.00M | $214.00M | -$78.00M | $74.00M | $28.00M |
| Net income | $233.00M | -$576.00M | $369.00M | $480.00M | $433.00M | $282.00M | $214.00M | -$217.00M |
| EBITDA | $959.00M | $10.00M | $891.00M | $560.00M | $1.13B | $706.00M | $763.00M | $240.00M |
| EPS (basic) | 0.20 | -0.49 | 0.32 | — | 0.38 | 0.25 | 0.19 | — |
| EPS (diluted) | 0.20 | -0.49 | 0.31 | — | 0.37 | 0.24 | 0.18 | — |
| Weighted avg. shares (diluted) | 1.18B | 1.17B | 1.18B | — | 1.16B | 1.16B | 1.16B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.08B | $3.65B | $3.74B | $3.56B | $2.20B | $2.16B | $1.70B | $3.30B |
| Receivables | $3.84B | $3.49B | $3.39B | $3.71B | $3.81B | $3.56B | $3.38B | $3.06B |
| Inventory | $3.17B | $3.22B | $3.18B | $3.18B | $3.32B | $3.50B | $3.25B | $3.01B |
| Current assets | $14.60B | $13.76B | $13.71B | $13.95B | $12.74B | $12.62B | $11.53B | $12.55B |
| PP&E, net | $3.75B | $3.93B | $4.00B | $4.08B | $4.82B | $4.81B | $4.63B | $4.58B |
| Goodwill | $15.74B | $15.84B | $15.82B | $16.00B | $15.95B | $15.95B | $15.48B | $16.00B |
| Intangibles | $3.30B | $3.45B | $3.61B | $3.78B | $3.94B | $4.14B | $4.19B | $4.42B |
| Total assets | $40.04B | $39.86B | $40.04B | $40.75B | $39.86B | $40.13B | $38.41B | $39.33B |
| Current liabilities | $15.43B | $15.65B | $13.53B | $13.46B | $11.49B | $11.86B | $11.16B | $12.80B |
| Short-term debt | $4.04B | $4.50B | $2.61B | $1.82B | $24.00M | $464.00M | $421.00M | $1.78B |
| Total liabilities | $32.06B | $32.10B | $31.81B | $32.83B | $32.60B | $33.30B | $32.15B | $33.61B |
| Shareholders' equity | $7.98B | $7.75B | $8.23B | $7.91B | $7.25B | $6.83B | $6.26B | $5.37B |
| Cash flow statement | ||||||||
| Operating cash flow | $241.00M | $411.00M | -$40.00M | $1.16B | $369.00M | $227.00M | -$105.00M | $575.00M |
| Capital expenditure | $120.00M | $104.00M | $168.00M | $142.00M | $136.00M | $96.00M | $127.00M | $129.00M |
| Free cash flow | $121.00M | $307.00M | -$208.00M | $1.02B | $233.00M | $131.00M | -$232.00M | $446.00M |
| Investing cash flow | $210.00M | -$491.00M | $229.00M | $165.00M | $135.00M | $236.00M | $201.00M | $202.00M |
| Financing cash flow | $6.00M | -$1.00M | $13.00M | $40.00M | -$453.00M | $6.00M | -$1.74B | -$674.00M |
| Depreciation & amortization | $245.00M | $241.00M | $239.00M | $260.00M | $249.00M | $251.00M | $244.00M | $269.00M |
| Stock-based compensation | $38.00M | $40.00M | $43.00M | $51.00M | $34.00M | $38.00M | $34.00M | $34.00M |
Free plan shows the latest 8 periods; Pro shows all 76 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.